|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Importantly, in vivo treatment experiments showed that one of the new immunotoxins could efficiently halt tumor growth at doses lower than 0.75 mg/kg, and it had a maximum tolerated dose (MTD) higher than 8.0 mg/kg, showing a substantially improved MTD and a broadened therapeutic window than the previously reported anti-HER2 immunotoxins.
|
31836485 |
2020 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
TN tumors had a higher metabolic activity than HER2 and luminal tumors but no significant differences in global BF values were noted.
|
31396665 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The 3D tumor model comprising EpCAM(+)/HER2(+) CTC subsets developed in this study has a promising potential to be used for investigation of an aggressive CTC microenvironment in vitro that mimics in vivo characteristics to test new drug candidates against CTCs.
|
31583566 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In early disease, HER2-E represented 83.8% and 44.7% of ERBB2-high and ERBB2-low tumors, respectively.
|
31037288 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Our findings suggest that the 2018 update represents a potentially significant change in therapeutic options for a substantial proportion of patients with 2.9% of FISH-positive tumors according to the 2007 and 2013 guidelines now categorized as HER2 negative and, thus, ineligible for HER2-targeted therapy.
|
31375912 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We have used a platform of HER2 targeted therapies resistant cell lines and primary cultures of healthy and tumor associated fibroblast to identify new potential targets related to tumor escape from anti-HER2 therapies Results: We have shown that tumor associated fibroblasts (TAFs) promote resistance to HER2-targeted therapies.
|
31699826 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Tumor-infiltrating lymphocytes (TILs) have recently been shown to predict late recurrence in HR+, counter to the findings that TILs confer good prognosis in TNBC and human epidermal growth factor receptor 2 positive (HER2+) subtypes.
|
31502168 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Heterogeneity of HER2 protein expression was observed in 38% of HER2-positive tumors, and a lateral/basolateral membranous staining pattern was common.
|
31477811 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Moreover, PTPN2 deletion in T cells expressing a chimeric antigen receptor (CAR) specific for the oncoprotein HER-2 increased the activation of the Src family kinase LCK and cytokine-induced STAT-5 signalling, thereby enhancing both CAR T-cell activation and homing to CXCL9/10-expressing tumours to eradicate HER-2<sup>+</sup> mammary tumours in vivo.
|
31803974 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
|
31653641 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However when attached to trastuzumab or pertuzumab, MMAF was as efficacious as MMAE in blocking HER2 expressing tumor cells in G2/M.
|
31597712 |
2020 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Despite this achievement, general principles from proposed systems pharmacokinetic modeling for intracellular processing of ADCs indicate potential shortcomings of T-DM1: (i) <i>C</i><sub>max</sub> limited by toxicities; (ii) slow internalization rate; (iii) resistance mechanisms due to defects in intracellular trafficking [loss of lysosomal transporter solute carrier family 46 member 3, (SLC46A3)], and increased expression of drug transporters MDR1 and MRP1; and (iv) lack of payload bystander effects limiting utility in tumors with heterogeneous HER2 expression.
|
31582515 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The patients with TNBC or HER2 subtype showed increased number of immune checkpoint ligand-receptor interactions between tumor and immune cells.
|
31767471 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
A reliable risk stratification on the basis of tumor biology and host factors of HER2-positive (HER2<sup>+</sup>) early breast cancer (eBC) patients is needed.
|
31378534 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Besides, the LDHC level in exosomes of BC patients associated with tumor size, and positively correlated with HER2 and Ki-67 expressions (all with P < 0.05).
|
31794764 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Dual HER2 and CDK7 inhibition induced tumor regression in two HER2iR BC xenograft models in vivo.
|
31462705 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
HER2 status was associated with primary tumor location (P = 0.037), regional lymph node metastasis (P = 0.035), and TNM stage (P = 0.022) in CRCs based on the HERACLES criteria.
|
31720832 |
2020 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Introduction of the ERBB2 mutations encoding protein variants S310F, S423R, R678Q, Q679L, E717D, L755S, V777L and V842I into human pancreatic epithelial cells causes oncogenic transformation, increasing ERBB2 signaling, anchorage-independent cell growth and tumor xenograft growth in nude mice, demonstrating that they are activating mutations.
|
31046123 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
[<sup>111</sup>In]In-Bn-DTPA-nimotuzumab was effective for treatment of TNBC or trastuzumab-resistant HER2-positive human BC tumors in mice that overexpress EGFR at administered amounts that caused no decrease in body weight or normal tissue toxicity in non-tumor-bearing Balb/c mice.
|
31706737 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Age under 35 (p <.001), small size tumor at diagnosis (p=.006) and subtype HER2 (p <.001) were associated with higher rates of CPR in bivariate analysis.
|
31732125 |
2020 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
High KANK1 protein expression was correlated with smaller tumour size and HER2 negativity, and better outcome in terms of longer breast cancer-specific survival [p = 0.013, HR 0.7, 95% CI 0.536-0.893] and time to distant metastasis [p = 0.033, HR 0.65, 95% CI 0.51-0.819].
|
31679074 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Although it may be slightly more cost-effective, its role in the treatment of HER2-overexpressing tumors requires further study in those at the extremes of body weight due to differences in drug exposure compared to IV trastuzumab.
|
31595774 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In multivariate analysis, age >70 years (vs <50 years; HR = 1.40; 95% CI: 1.24-1.57), triple-negative tumours (vs HER2-/HR+; HR = 1.87; 95% CI: 1.71-2.06), HER2+/HR-tumours (vs HER2-/HR+; HR = 1.14; 95% CI: 1.02-1.27), ≥3 metastatic sites (vs < 3; HR = 1.32; 95% CI: 1.21-1.43) and ≥3 previous treatment lines (vs < 3; HR = 1.75; 95% CI: 1.56-1.96) were detrimental for NPFS.
|
31835235 |
2020 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Vascularity score was independently associated with tumor size (p = 0.010) and HER2 (p = 0.007).
|
31300357 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Tumor uptake was evaluated by in vitro uptake assay in A549 cells and H23 cells (HER2-negative), and by in vivo biodistribution and SPECT imaging in A549 and H23 tumor-bearing mice.
|
30578135 |
2020 |